Filing Details

Accession Number:
0001570562-24-000031
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-23 20:27:59
Reporting Period:
2024-02-21
Accepted Time:
2024-02-23 20:27:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1570562 Evolus Inc. EOLS Pharmaceutical Preparations (2834) 461385614
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1700836 David Moatazedi 520 Newport Center Dr.
Suite 1200
Newport Beach CA 92660
See Remarks Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-21 61,202 $0.00 800,122 No 4 A Direct
Common Stock Disposition 2024-02-22 7,706 $13.08 792,416 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. Represents shares issuable on settlement of performance restricted stock units ("PSUs") granted to the reporting person in January 2023. The Issuer's Compensation Committee certified that the reporting person had achieved the set corporate development goal as of December 20, 2023. One-third of the PSU (20,401 shares) was delivered on February 21, 2024 after certification of the milestone being achieved. The remaining two-thirds will vest annually on the anniversary of December 20, 2023 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
  2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the PSUs.